Thank you for subscribing!
Next Investors Jun 01, 2022
Our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), yesterday recruited its first patient for its Phase 3 FSGS trial - a big step forward towards our #1 Objective for the company.
Wise-Owl May 20, 2022
BOD has just began two clinical trials, we are hoping for a re-rate on results of these trials. BOD dosed the first patients for the following trials in the last month for Insomnia (Phase 2b) and Long-COVID (Open label).
Finfeed Feb 28, 2022
Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.
Next Investors Feb 28, 2022
Get expert stock analysis direct in your inbox
Finfeed Archived Jun 08, 2021
Creso Pharma's (ASX: CPH) targeted acquisition company Halucenex intends to expand its phase II clinical trial to include non-veterans.
Finfeed Archived May 06, 2021
Creso Pharma Limited (ASX: CPH, FRA:1X8) has today announced that its acquisition target Halucenex Life Sciences Inc. has signed an agreement with Nucro-Technics, a Pharmaceutical Contract Research Organization (CRO) that is a partner to pharmaceutical, biologic, and medical device companies located all over the world.
Catalyst Hunter Archived May 05, 2021
Neurotech International Ltd (ASX: NTI) has begun its first clinical trials on children aged between 5 and 17 years with Autism Spectrum Disorder (ASD) for its unique cannabis strain.
Finfeed Archived Dec 16, 2020
Neurotech International Limited (ASX:NTI) has commenced a stage 1 clinical product formulation and development studies and anticipates entering clinical trials in the March quarter next year.
Finfeed Archived Apr 17, 2020
PharmAust Limited (ASX: PAA) has entered into a Materials Transfer Agreement with the Walter and Eliza Hall Institute of Medical Research (WEHI) to test the effects of monepantel (MPL) on COVID-19 infections.
Join Our Mailing List
